Minipress XL 5 mg (Tablet (Extended Release))

Unit Price: ৳ 21.18 (2 x 15: ৳ 635.40)

Strip Price: ৳ 317.70

Medicine Details

Treatment of essential (primary) hypertension
Treatment of secondary hypertension
Treatment of left ventricular failure
Treatment of Raynaud's phenomenon and Raynaud's disease
Adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia

Causes decrease in total peripheral vascular resistance
Selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle
Blood pressure lowering in supine and standing positions
Reduction in left ventricular filling pressure
Reduction in cardiac impedance
Improves urinary pressure profile in men

Therapy initiated with a low starting dose
Dosage adjusted according to the patient's individual toleration
Maintenance dosage given as a twice or three times daily regimen
Recommended starting dosage for left ventricular failure
Use daily maintenance dosage for left ventricular failure
Recommended starting dosage for Raynaud's phenomenon and Raynaud's disease
Usual daily maintenance dosage for Raynaud's phenomenon and Raynaud's disease
Recommended starting dose for benign prostatic hyperplasia
Recommended starting dose for Prazosin XR Extended-Release Tablets
Maintenance dose for Prazosin XR Extended-Release Tablets
Patients controlled on Prazosin Tablets alone or in combination with other antihypertensive medications may be switched to Prazosin XR Extended Release Tablets

No adverse drug interaction observed in clinical experience
Administered without adverse drug interaction with cardiac-glycosides, hypoglycemic agents, tranquilizers and sedatives, antiarrhythmic agents, analgesic, antipyretic, and anti-inflammatory agents

Common reactions include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea
Other reactions associated with Minipress XL therapy
Nervousness, vertigo, hallucinations, depression, rash, urinary frequency, impotence, incontinence, priapism, blurred vision, dry mouth, fever, arthralgia

Postural hypotension reported with the commencement of therapy
Recommendation for careful monitoring of blood pressure
Left ventricular failure patients may experience a clinical efficacy diminishment after several months of treatment

Not recommended for the treatment of children under the age of 12 years
Not recommended for left ventricular failure due to mechanical obstruction
Adequate data not yet available for left ventricular failure due to a recent myocardial infarction

Accidental ingestion of at least 50 mg of Minipress XL in a two-year child resulted in profound drowsiness and depressed reflexes
No decrease in blood pressure was noted